Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 1
2016 2
2018 4
2019 2
2020 3
2021 1
2022 5
2023 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

18 results

Results by year

Filters applied: . Clear all
Page 1
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer.
Modi S, Jacot W, Yamashita T, Sohn J, Vidal M, Tokunaga E, Tsurutani J, Ueno NT, Prat A, Chae YS, Lee KS, Niikura N, Park YH, Xu B, Wang X, Gil-Gil M, Li W, Pierga JY, Im SA, Moore HCF, Rugo HS, Yerushalmi R, Zagouri F, Gombos A, Kim SB, Liu Q, Luo T, Saura C, Schmid P, Sun T, Gambhire D, Yung L, Wang Y, Singh J, Vitazka P, Meinhardt G, Harbeck N, Cameron DA; DESTINY-Breast04 Trial Investigators. Modi S, et al. Among authors: sun t. N Engl J Med. 2022 Jul 7;387(1):9-20. doi: 10.1056/NEJMoa2203690. Epub 2022 Jun 5. N Engl J Med. 2022. PMID: 35665782 Free PMC article. Clinical Trial.
Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer.
Cortés J, Kim SB, Chung WP, Im SA, Park YH, Hegg R, Kim MH, Tseng LM, Petry V, Chung CF, Iwata H, Hamilton E, Curigliano G, Xu B, Huang CS, Kim JH, Chiu JWY, Pedrini JL, Lee C, Liu Y, Cathcart J, Bako E, Verma S, Hurvitz SA; DESTINY-Breast03 Trial Investigators. Cortés J, et al. N Engl J Med. 2022 Mar 24;386(12):1143-1154. doi: 10.1056/NEJMoa2115022. N Engl J Med. 2022. PMID: 35320644 Clinical Trial.
Antibody targeting of E3 ubiquitin ligases for receptor degradation.
Marei H, Tsai WK, Kee YS, Ruiz K, He J, Cox C, Sun T, Penikalapati S, Dwivedi P, Choi M, Kan D, Saenz-Lopez P, Dorighi K, Zhang P, Kschonsak YT, Kljavin N, Amin D, Kim I, Mancini AG, Nguyen T, Wang C, Janezic E, Doan A, Mai E, Xi H, Gu C, Heinlein M, Biehs B, Wu J, Lehoux I, Harris S, Comps-Agrar L, Seshasayee D, de Sauvage FJ, Grimmer M, Li J, Agard NJ, de Sousa E Melo F. Marei H, et al. Among authors: sun t. Nature. 2022 Oct;610(7930):182-189. doi: 10.1038/s41586-022-05235-6. Epub 2022 Sep 21. Nature. 2022. PMID: 36131013 Free PMC article.
The United States COVID-19 Forecast Hub dataset.
Cramer EY, Huang Y, Wang Y, Ray EL, Cornell M, Bracher J, Brennen A, Rivadeneira AJC, Gerding A, House K, Jayawardena D, Kanji AH, Khandelwal A, Le K, Mody V, Mody V, Niemi J, Stark A, Shah A, Wattanchit N, Zorn MW, Reich NG; US COVID-19 Forecast Hub Consortium. Cramer EY, et al. Sci Data. 2022 Aug 1;9(1):462. doi: 10.1038/s41597-022-01517-w. Sci Data. 2022. PMID: 35915104 Free PMC article.
Hyaluronic acid-doxorubicin nanoparticles for targeted treatment of colorectal cancer.
Pan DC, Krishnan V, Salinas AK, Kim J, Sun T, Ravid S, Peng K, Wu D, Nurunnabi M, Nelson JA, Niziolek Z, Guo J, Mitragotri S. Pan DC, et al. Among authors: sun t. Bioeng Transl Med. 2020 May 28;6(1):e10166. doi: 10.1002/btm2.10166. eCollection 2021 Jan. Bioeng Transl Med. 2020. PMID: 33532580 Free PMC article.
AKIMLpred: An interpretable machine learning model for predicting acute kidney injury within seven days in critically ill patients based on a prospective cohort study.
Sun T, Yue X, Zhang G, Lin Q, Chen X, Huang T, Li X, Liu W, Tao Z. Sun T, et al. Clin Chim Acta. 2024 May 1:119705. doi: 10.1016/j.cca.2024.119705. Online ahead of print. Clin Chim Acta. 2024. PMID: 38702035
When the AKIML(pred) included the nine features (NGAL, IGFBP7, sCysC, CAF22, KIM-1, NT-proBNP, IL-6, IL-18 and L-FABP) with the highest influence ranking, its model had the best prediction performance, with an AUC of 0.881 and an accuracy of 0.815 in training set, similarl …
When the AKIML(pred) included the nine features (NGAL, IGFBP7, sCysC, CAF22, KIM-1, NT-proBNP, IL-6, IL-18 and L-FABP) with the highe …
18 results